Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8 - 10, 2013 in Maryland, U.S.
TSX Venture: QPT
EDMONTON, Nov. 7, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces the presentation of a late-breaking abstract at the 28th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 9, 2013 in Maryland, U.S. The work was jointly developed by Stanford University, AIT Strategies and Quest as continuation of an exclusive license agreement between Stanford University and Quest to develop and market anti-MUC1 IgE technology for the treatment of cancer.
The title of the presentation is "MUC1 Specific IgE to Modify Myeloid Derived Cells of the Tumor Microenvironment". The licensed technology was developed by a team led by Joseph Mollick, M.D., Ph.D., formerly of Stanford University, and covers the use of immunotherapeutic IgE in development for treatment of patients with malignancies expressing the tumor-associated antigen MUC1, which is associated with cancer of the pancreas, colon, breast, lung, ovary, as well as multiple myeloma and others.
Dr, Mollick details the potential of the novel molecule to reprogram myeloid cells in the tumor microenvironment, leading to elimination of tumours and prevention of metastases. At the same time, the antibody can activate specific cellular immune responses directed against MUC1 originating in the tumor.
Quest is focusing its commercial efforts in the area of antibody mediated cancer immunotherapy with both IgG and IgE products. The Company recently licensed an anti-PSA IgE technology from the University of California at Los Angeles and Advanced Immune Therapeutics, Inc. Quest is currently conducting preclinical studies on anti-MUC1 IgE at the University of Nebraska Medical Center through a sponsored research contract to Professor Michael A. Hollingsworth. Quest also holds numerous patents for the use of tumor associated monoclonal antibodies as immune modulators. "Both IgG and IgE technologies are complementary and provide a novel approach for enhancing the effectiveness of chemotherapy while activating specific immunity to fight the cancer" commented Dr. Madi R. Madiyalakan, CEO of the Company.
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded, Canadian based clinical stage company developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants and photodynamic therapy. Quest has a body of clinical experience and a new appreciation of the obstacles and potential of combinatorial immunotherapeutic approaches to cancer by using either immunoglobulin G or E as immune modulators to enhance tumor specific immunity and clinical outcome.
The most advanced of its product candidates is oregovomab, an anti-CA125 monoclonal antibody, in combination with front-line chemotherapy for the treatment of advanced ovarian cancer which is currently undergoing a phase IIb clinical trial in 12 centers in Italy and the U.S. The Company's MUC1 program that has already undergone a phase I clinical trial has the potential to permit tumor specific immunization in more than 70% of all cancers that kill. Quest is also conducting a phase I clinical trial for the treatment of prostate cancer, with its photosensitizer, SL052.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
Share this article